Ethyl 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine-2-carboxylate;hydrochloride, 98+%, 100mg

N,N-Diethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine, 95.0%, 100mg

4-cyclopropyl-1-phenyl-1,6-dihydro-7H-pyrazolo[3,4-d]pyridazin-7-one, 95.0%, 2.5g

Diclorometano, mínimo 99,5 %, para síntesis, 100 ml, envase de vidrio

(S)-2-Amino-3-(3,5-dichlorophenyl)propanoic acid, 95.0%, 1g

tert-Butyl 3-(bromomethyl)benzylcarbamate, 95.0%, 250mg

tert-Butyl (3aS,7aR)-7-oxo-3,3a,4,5,6,7a-hexahydro-1H-isoindole-2-carboxylate, 95%, 1g

2-Methoxy-9-phenylacridine, 98%, 250mg

(S)-2-((2-Ethoxyphenoxy)methyl)morpholine hydrochloride, 98.0%, 10mg

1,3-Bis(4-methoxyphenyl)thiourea, 95.0%, 10g

(2-Ethoxy-3-formyl-5-methylphenyl)boronic acid, 95%, 1g

(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)-4-methoxytetrahydrofuran-3-ol, 98%, 250mg

N-(2-Oxopropyl)acetamide, 95.0%, 5g